Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21990075 | 0.84 | HPGD (0.59) | HPGDSTING1ALDH1A1ALOX15MAPT | |
| SCHEMBL20594674 | 0.83 | HPGD (0.55) | HPGDSTING1ALDH1A1ALOX15MAPT | |
| SCHEMBL21972677 | 0.81 | HPGD (0.57) | HPGDSTING1ALDH1A1ALOX15MAPT | |
| SCHEMBL21905607 | 0.81 | STING1 (0.61) | HPGDSTING1ALDH1A1MAPTPOLB | |
| SCHEMBL20594731 | 0.80 | HPGD (0.57) | HPGDSTING1ALDH1A1ALOX15MAPT | |
| SCHEMBL21990178 | 0.80 | RORC (0.50) | RORC | |
| SCHEMBL21990114 | 0.79 | RORC (0.48) | RORC | |
| SCHEMBL21990139 | 0.75 | STING1 (0.69) | HPGDSTING1ALDH1A1MAPTPOLB | |
| SCHEMBL21990048 | 0.72 | STING1 (0.63) | HPGDSTING1ALDH1A1MAPTPOLB | |
| SCHEMBL21905634 | 0.72 | STING1 (0.75) | HPGDSTING1ALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-06-04 | — | — | US | claimed |
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | STING1, IRF3, CGAS | HPGD 618/4885STING1 1/4885ALDH1A1 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.